Overview

This trial is active, not recruiting.

Condition gastric cancer
Treatment otsgc-a24
Phase phase 1/phase 2
Sponsor National University Hospital, Singapore
Collaborator Wakayama Medical University
Start date November 2010
End date November 2016
Trial size 23 participants
Trial identifier NCT01227772, GA04/26/10

Summary

Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve survival of patients with advanced Gastric Cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
otsgc-a24
OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
(Experimental)
The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
otsgc-a24
OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
(Experimental)
The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
otsgc-a24
OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.

Primary Outcomes

Measure
safety of OTSGC-24
time frame: within 4 weeks of treatment
Optimal dosing schedule
time frame: 1 year

Secondary Outcomes

Measure
Induction of specific cytotoxic T-lymphocyte (CTL) response
time frame: after 4 weeks and 12 weeks of vaccination

Eligibility Criteria

Male or female participants from 21 years up to 99 years old.

Inclusion Criteria: - Patients must have histologically or cytologically confirmed inoperable or metastatic adenocarcinoma of the stomach or lower third of the oesophagus refractory or intolerable to standard therapy. - Patients must have measurable or evaluable disease. - Age >= 201years - ECOG performance status of 0 to 2 - Life expectancy at least 3 months - Patients must have normal organ and marrow function as defined below: - absolute neutrophil count >=1,500/mcL - platelets >=100,000/mcL - total bilirubin within normal institutional limits - AST(SGOT)/ALT(SGPT) <=2.5 X institutional upper limit of - Normal creatinine within normal institutional limits - Patients must be HLA-A*2402 - Patients must have recover from all reversible treatment toxicity from prior chemotherapy, radiotherapy or surgery. - The effects of OTSGC-A24 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Patients receiving any other investigational agents. - History of significant gastrointestinal bleeding that required intervention within the prior 1 month is ineligible; inherited bleeding diathesis or coagulopathy. - Serious non healing wound and peptic ulcer disease - Previous history of intestinal perforation - Invasive procedures defined as follows (Insertion of a vascular access device is not considered major/minor surgery): - Major surgical procedure, open biopsy or significant traumatic injury =28 days prior to -registration - Anticipation of need for major surgical procedures during the course of the study - Core biopsy <=7 days - Minor surgery <=2 weeks - Symptomatic CNS metastasis - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg), symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction/cerebrovascular event (<=6 months prior to study entry), cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, long term systemic immunosuppressant or corticosteroid. - Women who are breast-feeding or pregnant are excluded from this study

Additional Information

Official title A Phase I/IIa Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer
Principal investigator Wei Peng Yong, MRCP, MB ChB
Description Although palliative chemotherapy improved the outcome of patients with advanced Gastric Cancer, the prognosis for this group of patients remains poor. Tumor specific antigens and angiogenesis pathway are potential targets for immunotherapy. A cocktail of peptide vaccines is selected to overcome gastric cancer's heterogeneous and enhance the anti-tumor effect. Five HLA-A*2402-binding peptide vaccines derived from tumor specific antigens and VEGFR1 are chosen based on the frequencies of their expressions in gastric cancer and the ability to induce specific cytotoxic T-lymphocytes. In preclinical model, both down regulation these targets with siRNA and active vaccination resulted in tumor regression. The purpose of the study is to evaluate the safety and optimal dosing schedule of a cancer vaccine cocktail, OTSGC-A24 targeting novel specific tumor antigens FOXM1, DEPDC1, KIF20A, URLC10 and VEGFR1 in advanced gastric cancer patients with HLA-2402 haplotype.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by National University Hospital, Singapore.